MSD K.K. (Japan)

Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland

AIMS: KEYNOTE-689 trial results demonstrated that neoadjuvant pembrolizumab followed by adjuvant pembrolizumab plus standard of care (NP/AP + SOC) significantly improved event-free survival (EFS) versus SOC alone in patients with locoregionally advanced head and neck squamous cel...

Association of medical visit frequency with cardiovascular events and mortality in patients with dyslipidaemia: a cohort study using a Japanese claims database

Abstract Background Dyslipidaemia is a major risk factor for cardiovascular and cerebrovascular diseases; however, the optimal frequency of medical visits remains unclear. Objective To examine whether medical visit frequency is associated with the incidence of cardiac events, cer...